284462-58-4

Upstream product

• 284462-89-1 4-(2-(N-isopropylcarbamoyl)-pyridin-4-yloxy)aniline 
• 16588-75-3 2-methoxy-5-trifluoromethylphenyl isocyanate 
• 349-65-5 2-Methoxy-5-trifluoromethyl-aniline 
• 586-78-7 para-nitrophenyl bromide 
• 350-46-9 4-Fluoronitrobenzene 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 284462-57-3 4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitrobenzene 

Downstream Products

• 1360099-37-1 1-(4-chlorobenzyl)-3-ethyl-4-methylthio-6-[4-(5-methoxycarbonyl-3-pyridyloxy)phenylimino]-1,3,5-triazine-2-(1H)-one 
• 1360099-35-9 1-(4-chlorobenzyl)-3-ethyl-6-[4-(5-methoxycarbonyl-3-pyridyloxy)phenylimino]-4-thioxo-1,3,5-triazinane-2-one 
• 611226-02-9 methyl-5-[4-(2,2,2-trifluoroacetamino)phenoxy]pyridine-3-carboxylate 

Relevant academic research and scientific papers

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent

Bis-aryl ureas have been disclosed previously as a potent class of Raf kinase inhibitors. Modifications in the amide portion led to an improvement in aqueous solubility, an important characteristic for an oral drug. Based on this finding, we hypothesize t

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.

Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.